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Abstract
The first barrier that an antimicrobial agent must overcome when interacting with its target is the
microbial cell wall. In the case of Gram-negative bacteria, additional to the cytoplasmic membrane
and the peptidoglycan layer, an outer membrane (OM) is the outermost barrier. The OM has an
asymmetric distribution of the lipids with phospholipids and lipopolysaccharide (LPS) located in
the inner and outer leaflets, respectively. In contrast, Gram-positive bacteria lack OM and possess
a much thicker peptidoglycan layer compared to their Gram-negative counterparts. An additional
class of amphiphiles exist in Gram-positives, the lipoteichoic acids (LTA), which may represent
important structural components. These long molecules cross-bridge the entire cell envelope with
their lipid component inserting into the outer leaflet of the cytoplasmic membrane and the teichoic
acid portion penetrating into the peptidoglycan layer. Furthermore, both classes of bacteria have
other important amphiphiles, such as lipoproteins, whose importance has become evident only
recently.
It is not known yet whether any of these amphiphilic components are able to stimulate the immune
system under physiological conditions as constituents of intact bacteria. However, all of them have
a very high pro-inflammatory activity when released from the cell. Such a release may take place
through the interaction with the immune system, or with antibiotics (particularly with those
targeting cell wall components), or simply by the bacterial division. Therefore, a given
antimicrobial agent must ideally have a double character, namely, it must overcome the bacterial
cell wall barrier, without inducing the liberation of the pro-inflammatory amphiphiles. Here, new
data are presented which describe the development and use of membrane-active antimicrobial
agents, in particular antimicrobial peptides (AMPs) and lipopolyamines. In this way, essential
progress was achieved, in particular with respect to the inhibition of deleterious consequences of
bacterial infections such as severe sepsis and septic shock.
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Introduction
Bacterial infections are still one of the major threats to human health worldwide. Bacterial
pathogens frequently cause severe diseases not only as primary agents, but also subsequent
to pathologies caused by other agents (superinfection such as ‘Spanish flu’, [1]). This fact is,
due, at least in part, to the increasing occurrence of bacterial resistance to antibiotics. In turn,
the spread of antibiotic resistant clones is greatly enhanced by the improper use of
antibiotics in daily medicinal practise and by the massive application of antibiotics in animal
husbandry [2]. Furthermore, in the last decades only two antibiotic classes with novel
mechanism of action have been marketed, and none of them are effective against Gram-
negative bacteria.
On the other hand, the antimicrobial activity of a given antibiotic does not correlate with its
ability to inactivate bacterial pathogenicity factors (PF) and interaction of some antibiotics
with their bacterial targets in vivo even enhance the release of PF into the extracellular
milieu. This frequently results in bacterial sepsis [8], a pathology that is the leading cause of
death in the critical care units of hospitals worldwide.
The cell wall is the first barrier that an antimicrobial agent must counteract [12]. In contrast
to Gram positive bacteria, Gram-negative organisms have an additional membrane, the so
called outer membrane (OM), that lies over and covers both the cytoplasmic membrane and
the peptidoglycan layer. The OM has an asymmetric distribution of the lipids with
phospholipids and lipopolysaccharide (LPS) located in the inner and outer leaflets,
respectively [13].
Gram-positive organisms lack OM and possess a much thicker peptidoglycan layer
compared to their Gram-negative counterparts [12]. The additional class of amphiphiles in
Gram-positives, the lipoteichoic acids (LTA), representing important structural components
[14], cross-bridge the entire cell envelope with their lipid component inserting into the outer
leaflet of the cytoplasmic membrane and the teichoic acid portion penetrating into the
peptidoglycan layer. The importance of another class of amphiphiles, the lipoproteins, has
become evident only recently [15]. Summarized, the main PF of Gram-negative bacteria is
the endotoxin (LPS, lipopolysaccharide), whereas lipoproteins (LP) rank among the most
important PF in Gram-positive. Therefore, an ideal antibiotic should combine a high
antimicrobial activity with a potent ability to bind and neutralize PF.
A promising approach to develop new effective drugs since the 1990’s is the use of AMPs
derived from binding domains of host defence proteins such as lactoferrin, NK-lysin, and
Limulus anti-LPS factor (LALF) [9], [10], [11]. Successive cycles of improvement rendered
compounds endowed with considerable antimicrobial and anti-endotoxic activity. In
addition, pathogens are frequently unable to develop resistance to these rapidly bactericidal
agents [3]. For instance, some pathogens such as Pseudomonas aeruginosa remain sensitive
only to polymyxins [4], although the systemic use of these AMPs is not widely accepted by
clinicians due to their alleged nephro- and neurotoxicity [5]. An important feature of the
majority of AMPs is their ability to bind to LPS and permeabilize the outer membrane (OM)
of Gram-negative bacteria thus sensitizing bacterial cells to co-administered compounds [6].
In addition, the ability of AMPs to kill cells in stationary phase enables them to be
bactericidal not only for planktonic cells but also for bacteria growing in biofilms [7]. Up to
now, however, available peptides lack a sufficiently high therapeutical index, which is
necessary to avoid detrimental side effects.
Whereas it is clear that amphiphilic components such as LPS and LTA provide important
permeability barrier functions, it has not been demonstrated that these molecules stimulate
the innate immune system as constituents of intact bacterial cell wall structures. However,
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all of them are highly active when released from the cell and this occurs either by the action
of the immune effector functions (such as complement-mediated lysis, opsonophagocytosis,
etc.), or by antibiotics, or simply by cell division of the bacteria. The clinical significance of
antibiotic-mediated release of these immunostimulatory and proinflammatory amphiphiles is
of high relevance [16], [17]. It is therefore desirable that antimicrobial regimens not only
exert bactericidal activity, but also either avoid release of proinflammatory cell wall-derived
amphiphiles, or sequester and neutralize them even as they are being released as a
consequence of microbial lysis and death.
We present data describing the development and use of dual-purpose membrane-active
antimicrobial agents and LPS/LP sequestrants, focusing on AMPs and lipopolyamines. Our
long-term goal is to evaluate these compounds either as single-agent antimicrobials or as
adjunctive chemotherapeutic agents that may have value in combination with bactericidal
antibiotics. These compounds have been shown to effectively neutralize LPS in vitro and to
protect mice from a lethal endotoxic shock in an animal model of acute sepsis. Different
aspects of the mechanisms of action in in vitro as well as in vivo systems are described in
this paper.
Peptide-induced inhibition of inflammation reaction
Lactoferricin-derived peptides
It has been previously shown that acylation of a lactoferricin-derived AMP leads to an
improvement both of the antimicrobial and LPS detoxification activities of the resultant
compound [18].
To confirm and expand these observations, we used LF11, an 11-amino acid
(FQWQRNIRKVR) peptide derived from human lactoferricin, as a template to design a
library of peptides and lipopeptides as described elsewhere [19, 20]. To study the influence
of acylation on the antimicrobial activity of the compounds we measured their minimum
inhibitory concentration (MIC) on Gram-negative and Gram-positive bacterial pathogens
grown under conventional (planktonic) culture conditions. In addition, we tested the ability
of the peptides and their acylated derivatives to reduce the viability of biofilms formed by
Pseudomonas aeruginosa PAO1 and/or to remove them. Results obtained with peptides
P2-15, P2-27, P2-29 and P2-33 (see Table 1) exemplified to a large extent the behaviour
observed with the entire library. In general, acylation neither increased the potency nor the
spectrum of antimicrobial activity of the compounds since lipopeptides had equal or worse
MIC than their parent molecules. These results show that sometimes acylation of a
lactoferricin-derived peptide can be detrimental for its antimicrobial performance as
opposed to previous observations with LF11 and its N-acyl derivative lauryl-LF11 [18]. In
addition, our data confirm conclusions of Japelj and collaborators reporting that in synthetic
lipopeptides the acyl chain represents an integral part of the molecular structure thus
influencing the shape of the lipopeptide for optimal interaction with bacterial membrane
[21]. Notably, the only organism that was more sensitive to the acylated than to the parent
compounds was Brucella abortus, a pathogen endowed with a lipopolysaccharide and a cell
envelope unconventional for a Gram-negative bacterium [22].
Testing the antimicrobial activity of compounds on biofilms instead of on planktonic cells
heightened the differences between peptides and lipopeptides. Thus, whereas the former
agents killed at least 95 % of cells and showed a significant biofilm-removing activity, most
lipopeptides displayed a very modest performance under the same conditions. The low anti-
biofilm activity of lipopeptides may be due to their higher affinity for alginate, a component
of the extracellular matrix of P. aeruginosa biofilm that has been reported to bind
hydrophobic compounds [23]. Additionally, it is possible that the higher molecular weight
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of the acylated compounds may hinder their penetration into the extracellular matrix of the
biofilm.
To study if acylation improved the OM-permeabilizing activity of peptides, we measured the
ability of all the compounds to act in synergy with novobiocin against P. aeruginosa. This
hydrophobic antibiotic cannot reach its intracellular target, gyrase, due to its inability to
cross an intact outer membrane. To quantify the synergistic effect, we determined the
Fractional Inhibitory Concentration (FIC) index of the peptide-novobiocin combinations.
The majority of authors consider a combination as synergistic when its FIC index is ≤ 0.5.
As shown in Table 1, acylation systematically resulted in compounds devoid of the potent
novobiocin-enhancing activity displayed by the parent peptides. In agreement with this
observation, Vaara and Vaara demonstrated that OM-permeabilizing activity does not
depend on acylation since PMBN, a deacylated derivative of PMB, is one of the most potent
permeabilizers known to date [24]. The exception to this behaviour was peptide P2-29, the
compound rendering the lowest MIC on the test strain (31.25 μg/mL). Lack of synergistic
activity of P2-29 could be due to the fact that its lethal (bactericidal) activity is so great that
it is not possible to observe non-lethal (permeabilization) activity, as it has been reported
previously [20].
In light of our results, one could conclude that acylation of peptides may be of minor
importance since it appears to lead to compounds lacking any meaningful biological
property. To the contrary, our data demonstrate that the ability to bind LPS in vivo and to
protect animals from a lethal endotoxic shock is strongly dependent on acylation (see Table
1). In all the cases, protection was associated with a very significant drop in TNFα serum
levels 60 min after inoculation of the lipopeptide (data not shown). These observations are in
good correlation with those mentioned above by Andrä and collaborators [18] and by
Tsubery and collaborators [25] reporting that lipopeptides display a much higher LPS
neutralizing activity compared to their non-acylated counterparts. The degree of protection
conferred by the lipopeptides was very high and homogenous with very few exceptions
(Table 1 and our unpublished results). Therefore, it was not possible to establish
relationships between antiendotoxic activity and the presence of a particular amino acid
sequence or acyl groups in the compounds. Our results demonstrate that acylation is
sufficient in most of the cases to turn a peptide with poor affinity towards LPS into a
compound endowed with potent anti-endotoxic activity in vivo.
Peptides based on Limulus anti-LPS factor and derivatives
For the development of suitable compounds to neutralize bacterial endotoxins a peptide
library was constructed which were originally based on the binding region of the Limulus
anti-LPS factor (LALF) [26]. The LALF was crystallized and the LPS-binding domain was
identified [27]. Ried et al [28] were the first authors reporting synthesis of peptides based on
this domain. They found that the complete binding sequence cLALF22 (amino acid
sequence 31–52 of LALF: GCHYRIKPTFRRLKWKYKGKFWCG) had the highest ability
to bind to the lipid A part of LPS, its ‘endotoxic principle’, whereas the shortened analogs
down to cLALF10 (LALF sequence 38–45, GCTFRRLKKCG) were much less active.
Andrä et al performed biophysical studies of the interaction of LALF (in recombinant form
called ENP = endotoxin-neutralizing protein) and part structures with endotoxins [9], [29],
[30], and found considerable inhibition of the biological activity of LPS at [ENP]:[LPS] 20
to 200:1 molar: Parallel to this, data on the aggregate supramolecular structure of LPS,
performed with synchrotron radiation small-angle X-ray scattering (SAXS), were indicative
of a change of the lipid A cubic structure into a more lamellar one. Importantly,
determination of the surface potential of LPS, the Zeta potential, which is a measure of the
accessible negative charges, showed an increase from −70 mV to positive values for lipid A
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and LPS Re. LALF-derived cyclic peptides were analysed in subsequent studies [31], [32],
starting with the compound with the complete LPS-binding domain (cLALF22) and various
shortened analogues. In all these studies the data consistently showed a change of the
endotoxin aggregate structure from preferentially cubic into a multilamellar one, as well as a
change of the morphologies of the LPS Re aggregates, as evidenced by freeze-fracture
electron microscopy, from ‘open egg-shells’ (i.e., spherical particles in the range 100 to 200
nm), into large stacks of some 1000 nm. The latter structures corresponded to the
multilamellae in the SAXS experiment with periodicities of 6.3 to 7.5 nm. With isothermal
titration calorimetry (ITC) the binding of the peptides to LPS in all cases was characterized
as an exothermic process, driven by the Coulomb interaction of the positive charges of
peptides with the negative charges of the endotoxins.
The terminal part of the shrimp anti-LPS-factor, a synthetic peptide with 24 AA, cyclic and
linear with a sequence Ac- ECKFTVKPYLKRFQVYYKGRMWCP, was analysed by Pan et
al [31]. Pre-treatment of mice with the cyclic compound led to a considerable enhancement
of survival of mice which had been infected with 1.28 · 106 cfu from Pseudomonas
aeruginosa, and the peptides were able to decrease the bacteria-induced production of TNFα
in the animals. Unfortunately, the peptides exhibited at a concentration of already 2 μg/ml
significant cytotoxicity in HeLa, MCF-7, and HT1080 cell lines, as measured by the MTT
test.
Due to the inability of the above described peptides to get a complete anti-se3ptic action, we
have designed and constructed a new series of 19’mer peptides. The biophysical analysis of
peptide 19-2 (sequence see Table 2) exhibited strong endotoxin binding, as deduced from
ITC experiments, resulting in a nearly complete blocking of the LPS-induced TNFα
production of human MNC at [Pep]:[LPS] 100:1 weight% [32]. A slightly shortened variant
exhibited much less anti-endotoxic activity, but considerably higher antibacterial activity.
This illustrates that the two parameters, antibacterial and anti-endotoxin activity, not
necessarily correlate.
The systematic study of various peptides differing in their amino acid chain lengths from 9
over 12 and 17 to 19, showed that the basic sequence, as given by Pep9, is already able to
confer a significant inhibition of the LPS-induced cytokine production (Fig. 1). However,
relatively high concentrations of the peptides were still necessary to inhibit cytokine
production and we found that we could improve peptide’s activity in this respect by
prolonging the peptide length with suitable amino acids. As can be seen in the Figures 1–2,
the increase in the AA acid chain lengths must be adapted to the physico-chemistry of the
lipid A part. To achieve this, the N-terminal side of the peptide must be composed
essentially of polar and basic AA, the C-terminal must be more hydrophobic. This alone,
however, is not enough, the exact number and type and sequence of AA is important, as
deduced from the comparison of the peptides with different chain lengths (Fig. 1) as well as
the comparison of Pep19-5, -6, and -7 (Fig. 2).
The importance of an exact length and composition of the AA to neutralize LPS is illustrated
by the results shown in Table 3, in which the action of two peptides with 17 AA is compared
with those of Pep19-2 in a mouse model of sepsis, yielding only protection for the longer
peptide.
Further improvements were obtained by modifications of the sequences (AA sequences see
Table 2), which led to a nearly complete inhibition of the LPS-induced cytokine secretion at
a [Pep]:[LPS] 3:1 molar ratio [33]. This is particularly evident in the case of the peptide
Pep19-2.5, our lead structure, which could protect animals in the mouse model of sepsis
already at a [Pep]:[LPS] ratio of 50:1 weight % (25 ng LPS and 1250 ng peptide). Also,
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peptides Pep19-2.2 and Pep19-12.1 were very effective in protecting animals in the animal
model of sepsis at peptide concentrations far below their threshold of cytotoxicity (Fig. 3).
These investigations were performed with a rough mutant LPS Ra from S. minnesota strain
R60. To assure that such strong inhibition activity takes also place for naturally occurring
heterogeneous smooth mutant LPS, the inhibition of the cytokine secretion induced by LPS
from E. coli O8:K27 was monitored by using the lead structure Pep19-2.5 (Fig. 4). As can
be seen, also for this endotoxin a considerable reduction of the LPS-induced concentration
of TNFα takes place already at [Pep]:[LPS] 3:1 weight %.
Since it was reported in literature, that peptides in a cyclic form, made by connecting two
cysteins via disulfide bridges, had higher cytokine inhibitory activity than the corresponding
linear peptides [34], we have constructed peptide Pep19-12.1 besides in its linear also in a
cyclic form by bridging the second Cys at the N-terminal with the third Cys as seen from the
C-terminal side (see Tab. 2). The comparison of the two peptides to inhibit the LPS-induced
cytokine reaction showed unequivocally (Fig. 5) that the cyclic form, although still active,
had significantly less ability to suppress the inflammation reaction.
Finally, for therapeutical use it would be of essential importance that some decrease of the
inflammation reaction takes place also, when the peptide is administered in a time-delayed
mode. Therefore, the peptide Pep19-2.2 was added at times 0 up to 3 h after the LPS
administration (whole incubation time 4 h). As can be deduced from Fig. 6, there is still a
considerable inhibition of the TNFα production even when the peptide is added 3 h after
LPS addition, despite the fact that the action of the peptide can take place only in the
remaining stimulation time of 1 h.
As mechanism of action for the ability of the peptides to neutralize endotoxins, the change
of lipid A / LPS cubic aggregate into a multilamellar structure was proposed, connected with
an extremely low saturation value of binding at [peptide]:[LPS] = 0.3 M/M, corresponding
to the binding saturation of 3 peptides with 10 LPS molecules [34]. Thus, human binding
proteins such as LBP and CD14 are no more able to bind to the LPS epitopes and thus
cannot initiate the inflammation reaction. Furthermore, the ability of the peptides to act even
after LPS administration is indicative of a membrane process of the interaction. This is
presently under investigation.
Neutralization of endotoxin by lipopolyamines
Recognition that membrane-active antimicrobial compounds may also possess LPS-
sequestering and -neutralizing activities was first identified with polymyxin B [36]. As
described above, a variety of cationic, amphipathic peptides share these properties, as was
evident with melittin, a basic, amphipathic peptide constituent of bee venom [37]. as well as
structurally unrelated peptides such as gramicidin S, tyrocidin, efrapeptin as well as de novo
designed peptides [38],[39],[40]. Hypothesizing that polycationicity and amphipathicity are
necessary and sufficient requirements for bacterial membrane perturbation and for LPS
sequestration, we turned our attention to small molecules embodying the above-mentioned
physical properties. Upon finding that bis-arg Gemini compounds indeed displayed
microbicidal and LPS-sequestering [41] activities, and that DOSPER, a model
lipopolyamine afforded protection in murine models of both purified LPS- and antibiotic-
induced LPS release models [42] led us eventually to a careful examination of the
lipopolyamine class of compounds typified by N-acyl or N-alkyl spermine or homospermine
[43], [44], [45],[46], [47], [48], [49],[50].
In examining a homologous series of mono- and bis-acyl polyamines, it was noted that the
carbon number (hydrophobicity) was a critical structural determinant of LPS-neutralizing
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potency [50]; for the mono-acyl 4 series of compounds, there was a progressive increase in
LPS-neutralizing potency (Fig. 7), while for the bis-acyl 8 series, the activity progressively
decreased with acyl chains longer than dodecyl (C12). It was of interest to probe possible
correlations with MICs against E. coli versus S. aureus. The results shown in Fig. 8 indicate
that against both organisms, a very similar structure-activity correlation is observed. Thus,
for the 4 compounds, acyl chain lengths from C12 to C16 result in maximal antimicrobial
efficacy against S. aureus, while maximal antibacterial effects are observed between C12 to
C14 against E. coli, with the activity falling off at C16, suggesting that the structural
requisites for optimal interaction with the Gram-negative outer membrane are rather
specific. For the 8 series, however, the converse is true with the short chain (C8–11)
analogues exhibiting maximal antibacterial effect (Fig. 9); the decline in activity in the
higher homologues in the 8 series is ascribable to progressive loss of aqueous solubility.
These structure-activity relationships of these compounds closely mirror that of LPS-
induced TNF-α and nitric oxide (NO) production in murine macrophages.[46] The
similarities of the 4 and 8 series between antimicrobial activity against Gram-negative
bacteria on the one hand, and sequestration of LPS on the other, suggest that the
antimicrobial activity is likely mediated via the interaction of these compounds with the
outer membrane [50].
Our primary interest in examining these compounds, however, lay not so much in evaluating
their intrinsic antimicrobial properties, but rather in understanding the mechanisms and
structure-activity relationships underlying their putative membrane permeabilizing action,
and in exploring the possibility of employing such compounds as adjuncts to conventional
antimicrobial chemotherapy for purposes of sequestering endotoxin released as a
consequence of Gram-negative bacterial lysis. We first investigated if the acylpolyamines
would act on both the inner membrane (IM) and the outer membrane (OM) [50], [51],
presumably as a consequence of nonspecific membranophilic effects as has been reported
for a variety of cationic amphipathic peptides such as melittin [37], defensins [51],
bactenecins [52] or, selectively perturb the OM in the manner of polymyxin B [53]. This is
shown in Fig. 8, a direct linear relationship was observed between OM and IM
permeabilizing activities [50]. Furthermore, these two events seem tightly coupled with
near-identical kinetics even under conditions of high osmotic strength. It is to be noted that
IM damage would necessarily require antecedent OM lysis.
Hypothesizing that compounds that sequester LPS could also bind to and inhibit LTA-
induced cellular activation, we screened congeneric series of polyamine sulfonamides which
we had previously shown effectively neutralized LPS both in vitro and in animal models of
endotoxemia. We observed that these compounds indeed bind and neutralize LTA, as
reflected by the inhibition of TLR2-mediated NF-κB induction in reporter gene assays.
Structure-activity studies showed a clear dependence of the acyl chain length on activity
against LTA in compounds with spermine and homospermine scaffolds [54]. We then
sought to examine possible correlations between the neutralizing potency toward LTA and
antimicrobial activity in S. aureus. A linear relationship between LTA sequestration activity
and antimicrobial activity for compounds with a spermine backbone was observed, while all
compounds with a homospermine backbone were equally active against S. aureus, regardless
of their neutralizing potency toward LTA [54]. These results suggest that the number of
protonatable charges is a key determinant of the activity toward the membranes of Gram-
positive bacteria.
The development of resistance to membrane-active antibiotics has been relatively slower
than that to conventional antibiotics, and it is possible that compounds such as the
acylpolyamines may be useful clinically, provided that they have an acceptable safety
profile and margin of safety. A more detailed understanding of the mechanisms of
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interactions of these compounds with LPS and LTA, as well as the Gram-negative and -
positive bacterial cell surfaces, will be instructive and should allow the rational design of
analogues which combine antisepsis and antibacterial properties.
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Figure 1.
Inhibition of the LPS-induced production of tumor-necrosis-factorα in human mononuclear
cells by peptides with different AA chain lengths at different [LPS]:[Pep] weight ratios.
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Figure 2.
Inhibition of the LPS-induced production of tumor-necrosis-factorα in human mononuclear
cells by peptides Pep19-5, Pep19-6, and Pep19-7 at different [LPS]:[Pep] weight ratios.
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Figure 3.
Survival of mice in the galactosamine model of endotoxin shock for Pep12-2 and Pep12.1 in
comparison to the gold standard| polymyxin B (PMB). LPS from Pseudomnas aeruginosa
was administered i.p. at a concentration of, and the peptides were added at a concentration
of
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Figure 4.
Inhibition of the tumor-necrosis-factorα in human mononuclear cells, induced by LPS from
E.coli O8:K27, by the lead peptide Pep19-2.5 at three different [LPS]:[Pep] weight ratios.
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Figure 5.
Inhibition of the LPS-induced production of tumor-necrosis-factorα in human mononuclear
cells by peptides Pep12.1 in linear and cycled form at different [LPS]:[Pep] weight ratios.
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Figure 6.
Inhibition of the LPS-induced production of tumor-necrosis-factorα in human mononuclear
cells by peptide Pep19-2.2, at t=0 and added time-delayed up to 3 h later (entire stimulation
time 4 hours). [LPS]:[Pep19-2.2] 1:100 weight%.
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Figure 7.
Structures of the mono-acyl (4 series) and bis-acyl (8 series) lipopolyamines (top).
Correlation of MIC against S. aureus and E. coli with length of the acyl group.
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Figure 8.
Antimicrobial activity of various lipopolyamines against E. coli and S. aureus.
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Figure 9.
Correlation of outer- (OM) and inner-membrane (IM) permeabilizing activity. OM
permeabilizing activity was determined using E. coli ML-35p (parent ATCC 43827
transformed with pBR322 vector encoding periplasmic β-lactamase); the leakage of
periplasmic β-lactamase activity was quantified using nitrocefin as a chromogenic substrate.
IM permeabilizing activity was determined using E. coli ML-35 using o-nitrophenyl-α-D-
galactopyranoside as the substrate to determine the α-galactosidase activity. Polymyxin B,
Polymyxin B nonapeptide (PMBN) and melittin were used as reference compounds.
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Table 2
Sequences of the Pep19 series
• Pep9 FRRLKWKFW
• Pep12-2 FRRLKWKKFWFW
• Pep17-1 KKFRRLKWKYKGKFWFW
Pep17-2 KKYRRFRWKFKGKFWFW
Pep17-3 RRYKKFKWRYRGRFWFW
• Pep19-2: GCKKYRRFRWKFKGKFWFWCG
• Pep19-2.2 GCKKYRRFRWKFKGKFWFW
• Pep19-2.5 GCKKYRRFRWKFKGKFWFWG
• Pep19-5: GKKYRRFRWKFRKGRFWFWG
• Pep19-6: GCKKFRRFKLKCKQKLWLWCG
Pep19-7: GKKYRRFWKFKGKWFWFWG
• Pep19-12: GCRRFKKFKKWRYRGRFWFWCFG
• Pep19-12.1 GCKKFRRFRRWKYKGKFWFWCFG
• Pep19-12.1cyclic GCKKFRRFRRWKYKGKFWFWCFG
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Table 3
Survival of mice
Peptide Dead mice/Number of mice after 48 h
LPS alone 10/10
LPS + Polymyxin B 0/10
LPS + Pep17-1 7/10
LPS + Pep17-2 7/10
LPS + Pep19-2 0/10
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